176
Participants
Start Date
March 1, 2023
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2027
Experimental drug
The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Control Rx
The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Anhui Provincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
The First People's Hospital of Foshan, Foshan
NOT_YET_RECRUITING
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
The Second Affiliated Hospital of Kunming Medical University, Kunming
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou
Sun Yat-sen University
OTHER